BMXX.Y Stock Overview

Develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. More details

BMXX.Y fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	1/6
Past Performance	2/6
Financial Health	6/6
Dividends	3/6

Rewards

Price-To-Earnings ratio (28.7x) is below the Medical Equipment industry average (36.2x)

Earnings are forecast to grow 12.91% per year

Risk Analysis

Shares are highly illiquid

Profit margins (10.4%) are lower than last year (16%)

My Notes

Capture your thoughts, links and company narrative

bioMérieux S.A. Competitors

Baxter International

NYSE:BAX

US$14.8b

Teleflex

NYSE:TFX

US$8.1b

Masimo

NasdaqGS:MASI

US$9.1b

STERIS

NYSE:STE

US$20.2b

Price History & Performance

Summary of share price highs, lows and changes for bioMérieux
Historical stock prices
Current Share Price	€9.51
52 Week High	€10.85
52 Week Low	€9.51
Beta	0.18
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-90.58%

Recent updates

Shareholder Returns

	BMXX.Y	US Medical Equipment	US Market
7D	0%	-1.5%	-2.4%
1Y	n/a	10.1%	23.3%

Return vs Industry: Insufficient data to determine how BMXX.Y performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how BMXX.Y performed against the US Market.

Price Volatility

Is BMXX.Y's price volatile compared to industry and market?
BMXX.Y volatility
BMXX.Y Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	7.6%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	3.1%

Stable Share Price: BMXX.Y has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine BMXX.Y's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1963	12,846	Pierre Boulud	www.biomerieux.com

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests.

bioMérieux S.A. Fundamentals Summary

How do bioMérieux's earnings and revenue compare to its market cap?
BMXX.Y fundamental statistics
Market cap	US$11.89b
Earnings (TTM)	US$414.06m
Revenue (TTM)	US$3.97b

28.7x

P/E Ratio

3.0x

P/S Ratio

Is BMXX.Y overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BMXX.Y income statement (TTM)
Revenue	€3.70b
Cost of Revenue	€1.63b
Gross Profit	€2.07b
Other Expenses	€1.68b
Earnings	€385.90m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	3.27
Gross Margin	55.93%
Net Profit Margin	10.43%
Debt/Equity Ratio	13.5%

How did BMXX.Y perform over the long term?

See historical performance and comparison

Dividends

0.9%

Current Dividend Yield

26%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/09/05 09:30
End of Day Share Price	2023/06/09 00:00
Earnings	2023/06/30
Annual Earnings	2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

bioMérieux S.A. is covered by 35 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Armelle Moulin	AlphaValue
Gaurav Jain	Barclays
Samuel England	Berenberg